-
51.发明公开
公开(公告)号：EP3960181A2
公开(公告)日：2022-03-02
申请号：EP21198646.8
申请日：2017-02-02
IPC分类号： A61K31/7048
摘要： A pharmaceutical composition for use in a method of treating an activated fibroblast associated disease or pre-disease condition in a mammal, the method comprising:
administering the pharmaceutical composition including a therapeutically effective amount of a first therapeutic;
wherein the first therapeutic is a YAP / TAZ inhibitor, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.-
公开(公告)号：EP3856045A1
公开(公告)日：2021-08-04
申请号：EP19865150.7
申请日：2019-09-25
-
公开(公告)号：EP3618850A1
公开(公告)日：2020-03-11
申请号：EP18794658.7
申请日：2018-05-01
IPC分类号： A61K38/17 , A61K45/06 , A61P27/02 , C07K14/705
-
54.发明公开
公开(公告)号：EP3582791A1
公开(公告)日：2019-12-25
申请号：EP18754890.4
申请日：2018-02-20
-
公开(公告)号：EP3472187A1
公开(公告)日：2019-04-24
申请号：EP17816042.0
申请日：2017-06-20
IPC分类号： C07K14/405 , C12N15/11 , C12N15/29 , C12N15/82 , C07H21/04
-
公开(公告)号：EP3463296A1
公开(公告)日：2019-04-10
申请号：EP17810867.6
申请日：2017-06-06
发明人： SOIN, Amol , KEVIL, Christopher , CHAN, Kyle , GIORDANO, Anthony
-
公开(公告)号：EP2831581B1
公开(公告)日：2018-10-03
申请号：EP13767904.9
申请日：2013-03-14
IPC分类号： G01N33/48 , G01N33/483 , G01N33/84
CPC分类号： G01N33/50 , G01N21/64 , G01N33/84 , G01N2021/7786 , Y10T436/184
摘要： A method to measure all relevant biologic hydrogen sulfide pools, namely free hydrogen sulfide, acid-labile sulfide, and bound sulfane sulfur, has been developed. This new method involves selective liberation, trapping and derivatization of labile hydrogen sulfide. The total labile sulfide, including the contribution of the bound sulfane sulfur pool, the acid-labile pool, and free H2S, was measured by incubating the sample with a reducing agent, TCEP (Tris(2-carboxyethyl)phosphine hydrochloride), to reduce disulfide bonds in an acid solution. This method was used to measure the three sulfide pools in blood samples from mice and from humans. This method can be used for research, environmental, and clinical diagnostic purposes in determining hydrogen sulfide bioavailability in biological or other samples.
-
公开(公告)号：EP3274091A1
公开(公告)日：2018-01-31
申请号：EP16769605.3
申请日：2016-03-23
申请人： The University of North Carolina at Chapel Hill , Cornell University , Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
发明人： SOPER, Steven, A. , BARANY, Francis , PARK, Sunggook , MURPHY, Michael , MCKINNEY, Collin, J. , EFCAVITCH, John, William , HUPERT, Mateusz
IPC分类号： B01L1/00 , B01L99/00 , C40B30/04 , C12M1/40 , G01N33/483 , G01N33/569
CPC分类号： G01N33/48721 , B01L3/5027 , B01L3/502715 , B01L3/502753 , B01L3/502761 , B01L2200/0647 , B01L2300/0645 , B01L2300/0861 , B01L2300/0896 , C12M1/40 , C12M23/16 , C12Q1/6806 , C12Q1/6837 , C12Q1/6869 , C12Q1/6874 , C12Q2561/125 , C12Q2565/629 , C12Q2565/631
摘要： The present invention is directed to a device that comprises a biomolecular processor and one or more nanotubes. Each biomolecular processor comprises a bioreactor chamber defined by a solid substrate, a plurality of spaced support structures within said bioreactor chamber and attached to the solid substrate, and one or more capture molecules immobilized to some or all of said plurality of spaced support structures, said one or more capture molecules suitable to bind to a portion of a target nucleic acid molecule in a sample. The device also comprises one or more nanotubes defined by the solid substrate and fluidically coupled to the bioreactor chamber.
-
公开(公告)号：EP2588133B1
公开(公告)日：2018-01-17
申请号：EP11730833.8
申请日：2011-06-29
申请人： Intervet International B.V. , Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
发明人： O'CONNELL, Kevin, A. , RAMACHANDRA, Rangappa, Narayana , GAUNT, Stephen, David , CORSTVET, Richard, E. , WASMOEN, Terri, Lee
CPC分类号： A61K39/0233 , A61K2039/521 , A61K2039/552 , A61K2039/55511 , A61K2039/57 , C12R1/01
摘要： Vaccine and/or immunogenic compositions that comprise an effective immunizing amount of an antigen from E. canis are described. In addition, methods of immunizing a subject against E. canis by providing the vaccine and/or immunogenic compositions are also disclosed.
-
60.发明公开USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY 有权VERWENDUNG VON MELANOCORTINEN ZUR BEHANDLUNG VONINSULINSENSITIVITÄT
公开(公告)号：EP2979703A1
公开(公告)日：2016-02-03
申请号：EP15179111.8
申请日：2008-11-05
申请人： IPSEN PHARMA S.A.S. , Board of Supervisors of Louisiana State University and Agriculture and Mechanical College
IPC分类号： A61K38/00
摘要： The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
摘要翻译： 本发明涉及黑皮质素受体，特别是melancortin-4受体的肽配体，因此可用于治疗对该受体的活化有反应的病症，例如胰岛素抵抗。
-
-
-
-
-
-
-
-
-
搜索结果
270 条记录 (耗时 0.023 秒)
